Matt Hoffman, Associate Editorial Director for NeurologyLive, has covered medical news for MJH Life Sciences, NeurologyLive’s parent company, since 2017. He hosts the NeurologyLive Mind Moments® podcast, as well as the Medical World News show, Deep Dive. Follow him on Twitter @byMattHoffman or email him at mhoffman@neurologylive.com
CMSC 2022: What to Expect From the Annual Meeting
May 25th 2022June Halper, MSN, APC-C, MSCN, FAAN, the chief executive officer of the Consortium of Multiple Sclerosis Centers, shared her perspective on what to expect from this year’s annual meeting, which takes place June 1-4, 2022, in National Harbor, Maryland.
AlzoSure Predict Test Shows Predictive Ability for Alzheimer Disease Years Prior to Diagnosis
May 17th 2022The blood test from Diadem SpA, which quantifies the AZ 284 peptide as readout of U-p53AZ, showed a significantly higher AUC in both time-independent and time-dependent prognostic analyses than gold standard testing.
The Potential of Sleepio and CBT in the Poststroke Recovery Process
May 14th 2022The cofounder and chief scientist at Big Health and professor of sleep medicine at the University of Oxford discussed the recent findings of a study of Sleepio in poststroke rehabilitation and the role that cognitive behavioral therapy could play in that care process.
An AI Morphology Array’s Potential to Improve Parkinson Diagnosis
May 13th 2022John F. Crary, MD, PhD, and Jerry Fernandez, MD, offer insight into PreciseDx's AI Morphology Feature Array and how this technology can improve neuropathology and diagnosis for neurodegenerative diseases, such as Parkinson disease.
Digital CBT Tool Sleepio Improves Sleep in Patients Undergoing Poststroke Rehabilitation
May 12th 2022The digital cognitive behavioral therapy improved sleep for almost half of the study cohort and showed additional signs of improvement for depression and anxiety among individuals in rehabilitation for stroke.
Rapid Progress in ALS: A Reflection of Advances in Neuromuscular Disorder Care
May 12th 2022With a burst of activity in recent months, the pipeline of development for amyotrophic lateral sclerosis has proven to be a miniature likeness of the wider progress being made in the care and management of neuromuscular disorders.
Steven Wolf, MD, on the State of Lennox-Gastaut Syndrome and the Improving the Diagnostic Process
May 8th 2022The director of the pediatric epilepsy program at Boston Children’s Health Physicians shared his expertise with the challenges associated with diagnosing LGS, how the REST-LGS tool may help, and the need to collect more data.
Axsome Issued CRL for AXS-07 in Acute Migraine Treatment
May 2nd 2022Axsome expects to address the concerns in the letter and plans to resubmit AXS-07. The MoSEIC meloxicam-rizatriptan combination significantly reduced migraine symptoms and pain compared with placebo and both active agents in a pair of phase 3 trials.
The Big Data Revolution’s Role in Developing a Personalized Medicine Model
April 29th 2022Shurjal Baxi, MD, MPH, the senior vice president of Clinical and Scientific Solutions at Verana Health, shared her perspective on the AAN’s Axon Registry and how quality data collection can drive improvements in patient care and management.
Regenerative Medicine for Neurologic Injury and the Potential of SB623
April 29th 2022Peter J. McAllister, MD, FAAN, medical director and chief medical officer, New England Center for Neurology and Headache, offered his insight into data from the phase 2 STEMTRA trial in TBI and the trends he’s observed in the field of regenerative medicine.
AAN Annual Meeting 2022: Top Expert Interviews
April 28th 2022Expert clinicians offer their insight on the associations between stroke and COVID-19, treatment for traumatic brain injury, the latest on aducanumab, priorities for research in migraine, and more, from the 2022 American Academy of Neurology Annual Meeting.
Patient Survey Suggests Preference for Once-Nightly Dosing With FT218 in Narcolepsy
April 27th 2022Patients who switched from a twice-nightly stable regimen of Xyrem or Xywav to once-nightly FT218 reported that they preferred the new dosing schedule, along with challenges in adherence to twice-nightly dosing.
Biogen Withdraws Aducanumab Application to EMA Shortly Following CMS National Coverage Determination
April 26th 2022Following an NCD that will allow for Medicare coverage of the therapy only in NIH- and FDA-approved studies and trials, Biogen has pulled its application to the European Medicines Agency for aducanumab treatment in Alzheimer disease.
Treatment Optimization in Epilepsy and the Need to Individualize the Approach
April 24th 2022Jacqueline A. French, MD, discussed the factors that influence the challenges in treatment selection in epilepsy, and how patient conversations and comprehension of heterogeneity can help in the treatment selection process.